Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
SNDX
#1702
Syndax Pharmaceuticals, Inc.
21.7
1
+6.89%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+6.89%
Monatliche Änderung
+1.92%
6 month change
+32.54%
Jahresänderung
+43.02%
Vorheriger Schlusskurs
20.3
1
Open
21.7
1
Bid
Ask
Low
21.7
1
High
21.7
1
Volumen
124
Märkte
Aktien
Gesundheitswesen
SNDX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
85.57 M
86.02 M
86.05 M
86.14 M
86.91 M
88.2 M
—
Valuation ratios
Enterprise value
—
983.16 M
903.1 M
698.08 M
1.22 B
1.72 B
4.54 B
Price to earnings ratio
-5.27
-3.55
-3.19
-2.41
-4.27
-6.39
-16.26
Price to sales ratio
102.62
47.8
24.09
10.3
11.9
—
—
Price to cash flow ratio
-6.13
-4.12
-3.67
-2.66
-4.26
5.64
-4.96
Price to book ratio
0.84
3.93
0.81
0.78
1.71
28.16
31.45
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.13
0.13
0.12
0.11
0.13
0.49
Return on equity %
0.23
0.33
0.39
0.46
0.53
1.05
2.43
Return on invested capital %
678.91
—
183.19
177.62
182.98
248.51
792.31
Gross margin %
100
100
100
100
100
100
400
Operating margin %
716.62
1 254.75
417.91
182.71
125.19
91.34
817.14
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
673.01
1 226.16
423.34
189.28
132.36
99.32
844.3
Liquidity ratios
Quick ratio
—
5.82
5.75
4.55
4.42
4.12
18.85
Current ratio
6.99
5.82
5.8
4.71
4.64
4.4
19.55
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.03
0.01
0.03
0.06
0.08
0.13
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.46
-0.01
-0.01
-0.01
-0.01
-0.04
Long term debt to total equity ratio
—
1.15
-0.03
-0.04
-0.05
-0.09
-0.21
Per share metrics
Operating cash flow per share
0.73
0.67
1.1
1.02
0.81
0.8
3.74
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.56
6.69
5.94
5.27
5.03
4.55
20.8
Net current asset value per share
4.86
7.04
6.37
6.16
6.12
6.1
24.74
Tangible book value per share
4.29
3.37
2.5
1.82
1.33
0.75
6.4
Working capital per share
4.16
5.83
5.27
4.85
4.8
4.71
19.63
Book value per share
4.29
3.37
2.5
1.82
1.33
0.75
6.4
Nachrichten
Syndax Pharmaceuticals: Stifel erhöht Kursziel aufgrund starker Medikamentenumsätze
Stifel raises Syndax Pharmaceuticals stock price target on drug sales
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax: Umsatz im 4. Quartal 2025 steigt um 50 %, Weg zur Profitabilität skizziert
Syndax Q4 2025 slides: revenue surges 50%, profitability path outlined
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals: Gewinn pro Aktie enttäuscht trotz starkem Umsatzwachstum
Syndax Pharmaceuticals: EPS verfehlt Schätzungen um 0,19 $ - Umsatz besser als erwartet
Syndax Pharmaceuticals earnings missed by $0.19, revenue topped estimates
Syndax vor Bewährungsprobe: Markteinführung neuer Krebsmedikamente im Fokus der Quartalszahlen
Syndax faces earnings test as cancer drug launches accelerate
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX)